 WEST LAFAYETTE, Ind., April 21, 2021 GLOBE NEWSWIRE -- Inotiv, Inc. NASDAQ:NOTV the Company, We, Our or Inotiv, a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the pricing of an underwritten public offering of 2,647,059 of its common shares at a price to the public of 17.00 per share. The gross proceeds to the Company from this offering, before deducting the underwriting discount and offering expenses payable by the Company, are expected to be approximately 45.0 million. All of the shares are being offered by the Company. The offering is expected to close on or about April 23, 2021. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 397,058 of its common shares at the public offering price, less the underwriting discount. 